GTCR Completes Acquisition of Zentiva to Accelerate Growth in Generics Pharmaceuticals

GTCR Completes Acquisition of Zentiva

GTCR, a prominent private equity firm, has successfully finalized its acquisition of Zentiva, a leading generics pharmaceutical company in Europe. This strategic move aims to enhance Zentiva's growth trajectory and reinforce its market leadership in the generics sector.

Zentiva, renowned for its commitment to developing, manufacturing, and supplying a wide range of generic, branded specialty, and over-the-counter medicines, caters to the healthcare needs of more than 100 million patients across over 40 countries. The company's robust research and development capabilities, coupled with a steadfast dedication to clinical excellence and product quality, underpin its esteemed reputation in the pharmaceutical landscape.

In this partnership, GTCR will collaborate closely with Zentiva's management team, which is spearheaded by Chief Executive Officer Steffen Saltofte and Executive Chairperson Kieran Murphy. Both leaders bring a wealth of experience from their backgrounds in healthcare businesses, including positions at Acino and GE HealthCare. This collaboration signifies a pivotal juncture for Zentiva as it looks to further its growth and expand its product offerings.

GTCR's Commitment to Healthcare

With a 45-year track record in healthcare investments, GTCR has consistently showcased its ability to support businesses in the pharmaceutical sector. The firm's commitment to investing in Zentiva will focus on promoting new product development, expanding the company’s portfolio, and enhancing its geographic reach. This initiative is not only aimed at improving access to essential medicines but also at fostering sustainable healthcare systems for the communities they serve.

Steffen Saltofte, CEO of Zentiva, expressed enthusiasm about the new chapter for the company, stating, _“We are proud of Zentiva's strong history and footprint. We look forward to partnering with GTCR at an important inflection point following several years of growth.”_ He emphasized the potential for accelerating the momentum with GTCR's industry expertise.

Sean Cunningham, Managing Director and Head of Healthcare at GTCR, highlighted the integral role Zentiva plays in delivering high-quality, cost-effective therapies. With the rising focus on the accessibility of essential medicines, Zentiva's competitive edge through its manufacturing capabilities makes it poised for long-term growth and impactful contributions to public health.

Transition and Future Prospects

Tom Allen, Managing Director at Advent, the previous owner of Zentiva, expressed pride in what the company has achieved during their partnership, noting its transformation into a scalable and competitive generator of affordable medicines. His acknowledgment of the dedication of Zentiva’s personnel reflects the deep-rooted commitment of the team towards the company’s mission.

In preparation for this acquisition, GTCR enlisted the expertise of advisors such as Barclays Bank PLC and BNP Paribas, with Morgan Stanley Co. LLC serving as a financial advisor. Conversely, Advent engaged Goldman Sachs and PJT Partners as primary advisors alongside Freshfields providing legal counsel.

About GTCR and Zentiva

Founded in 1980, GTCR employs a fundamental strategy focusing on investing in and empowering management leaders. Since its inception, it has committed over $30 billion to about 300 companies across various sectors including healthcare. The firm manages approximately $50 billion in equity capital and is headquartered in Chicago with additional offices in New York and West Palm Beach.

Zentiva, established with a focus on enhancing health and well-being, operates with integrity across four manufacturing sites and a vast network of external partners. The company’s workforce of over 5,400 individuals embodies a united front dedicated to ensuring the delivery of quality medicines to those who need them most.

As the partnership unfolds, both GTCR and Zentiva are optimistic about the future, committed to expanding access to essential medicines and fostering a healthier society for all.